BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1325 related articles for article (PubMed ID: 24076216)

  • 21. Sophocarpine inhibits tumor progression by antagonizing the PI3K/AKT/mTOR signaling pathway in castration-resistant prostate cancer.
    Weng M; Shi C; Han H; Zhu H; Xiao Y; Guo H; Yu Z; Wu C
    PeerJ; 2022; 10():e14042. PubMed ID: 36132221
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CD44 variant 6 is associated with prostate cancer growth and chemo-/radiotherapy response in vivo.
    Ni J; Cheung BB; Beretov J; Duan W; Bucci J; Malouf D; Graham P; Li Y
    Exp Cell Res; 2020 Mar; 388(2):111850. PubMed ID: 31954695
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Angiogenin interacts with ribonuclease inhibitor regulating PI3K/AKT/mTOR signaling pathway in bladder cancer cells.
    Peng Y; Li L; Huang M; Duan C; Zhang L; Chen J
    Cell Signal; 2014 Dec; 26(12):2782-92. PubMed ID: 25193113
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CEACAM6 promotes gastric cancer invasion and metastasis by inducing epithelial-mesenchymal transition via PI3K/AKT signaling pathway.
    Zang M; Zhang B; Zhang Y; Li J; Su L; Zhu Z; Gu Q; Liu B; Yan M
    PLoS One; 2014; 9(11):e112908. PubMed ID: 25398131
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Non-immunosuppressive triazole-based small molecule induces anticancer activity against human hormone-refractory prostate cancers: the role in inhibition of PI3K/AKT/mTOR and c-Myc signaling pathways.
    Leu WJ; Swain ShP; Chan SH; Hsu JL; Liu SP; Chan ML; Yu CC; Hsu LC; Chou YL; Chang WL; Hou DR; Guh JH
    Oncotarget; 2016 Nov; 7(47):76995-77009. PubMed ID: 27769069
    [TBL] [Abstract][Full Text] [Related]  

  • 26. HPIP promotes epithelial-mesenchymal transition and cisplatin resistance in ovarian cancer cells through PI3K/AKT pathway activation.
    Bugide S; Gonugunta VK; Penugurti V; Malisetty VL; Vadlamudi RK; Manavathi B
    Cell Oncol (Dordr); 2017 Apr; 40(2):133-144. PubMed ID: 28039608
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Knockdown of tripartite motif 59 (TRIM59) inhibits proliferation in cholangiocarcinoma via the PI3K/AKT/mTOR signalling pathway.
    Shen H; Zhang J; Zhang Y; Feng Q; Wang H; Li G; Jiang W; Li X
    Gene; 2019 May; 698():50-60. PubMed ID: 30822475
    [TBL] [Abstract][Full Text] [Related]  

  • 28. γ-Glutamyl cyclotransferase contributes to tumor progression in high grade serous ovarian cancer by regulating epithelial-mesenchymal transition via activating PI3K/AKT/mTOR pathway.
    Li Y; Wu T; Wang Y; Yang L; Hu C; Chen L; Wu S
    Gynecol Oncol; 2018 Apr; 149(1):163-172. PubMed ID: 29429592
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CEP55 promotes epithelial-mesenchymal transition in renal cell carcinoma through PI3K/AKT/mTOR pathway.
    Chen H; Zhu D; Zheng Z; Cai Y; Chen Z; Xie W
    Clin Transl Oncol; 2019 Jul; 21(7):939-949. PubMed ID: 30607788
    [TBL] [Abstract][Full Text] [Related]  

  • 30. GABARAPL1 suppresses metastasis by counteracting PI3K/Akt pathway in prostate cancer.
    Su W; Li S; Chen X; Yin L; Ma P; Ma Y; Su B
    Oncotarget; 2017 Jan; 8(3):4449-4459. PubMed ID: 27966458
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CAV-1 contributes to bladder cancer progression by inducing epithelial-to-mesenchymal transition.
    Liang W; Hao Z; Han JL; Zhu DJ; Jin ZF; Xie WL
    Urol Oncol; 2014 Aug; 32(6):855-63. PubMed ID: 24968949
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dual PI3K/mTOR inhibitor NVP-BEZ235 sensitizes docetaxel in castration resistant prostate cancer.
    Yasumizu Y; Miyajima A; Kosaka T; Miyazaki Y; Kikuchi E; Oya M
    J Urol; 2014 Jan; 191(1):227-34. PubMed ID: 23954373
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Activation of PI3K-Akt signaling pathway promotes prostate cancer cell invasion.
    Shukla S; Maclennan GT; Hartman DJ; Fu P; Resnick MI; Gupta S
    Int J Cancer; 2007 Oct; 121(7):1424-32. PubMed ID: 17551921
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MiR-129 inhibits cell proliferation and metastasis by targeting ETS1 via PI3K/AKT/mTOR pathway in prostate cancer.
    Xu S; Ge J; Zhang Z; Zhou W
    Biomed Pharmacother; 2017 Dec; 96():634-641. PubMed ID: 29035829
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Epithelial cell-derived periostin functions as a tumor suppressor in gastric cancer through stabilizing p53 and E-cadherin proteins via the Rb/E2F1/p14ARF/Mdm2 signaling pathway.
    Lv H; Liu R; Fu J; Yang Q; Shi J; Chen P; Ji M; Shi B; Hou P
    Cell Cycle; 2014; 13(18):2962-74. PubMed ID: 25486483
    [TBL] [Abstract][Full Text] [Related]  

  • 36. GOLM1 promotes prostate cancer progression through activating PI3K-AKT-mTOR signaling.
    Yan G; Ru Y; Wu K; Yan F; Wang Q; Wang J; Pan T; Zhang M; Han H; Li X; Zou L
    Prostate; 2018 Feb; 78(3):166-177. PubMed ID: 29181846
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ginkgolic Acid Inhibits Invasion and Migration and TGF-β-Induced EMT of Lung Cancer Cells Through PI3K/Akt/mTOR Inactivation.
    Baek SH; Ko JH; Lee JH; Kim C; Lee H; Nam D; Lee J; Lee SG; Yang WM; Um JY; Sethi G; Ahn KS
    J Cell Physiol; 2017 Feb; 232(2):346-354. PubMed ID: 27177359
    [TBL] [Abstract][Full Text] [Related]  

  • 38. FAM83D promotes epithelial-mesenchymal transition, invasion and cisplatin resistance through regulating the AKT/mTOR pathway in non-small-cell lung cancer.
    Yin C; Lin X; Wang Y; Liu X; Xiao Y; Liu J; Snijders AM; Wei G; Mao JH; Zhang P
    Cell Oncol (Dordr); 2020 Jun; 43(3):395-407. PubMed ID: 32006253
    [TBL] [Abstract][Full Text] [Related]  

  • 39. TROP2 promotes proliferation, migration and metastasis of gallbladder cancer cells by regulating PI3K/AKT pathway and inducing EMT.
    Li X; Teng S; Zhang Y; Zhang W; Zhang X; Xu K; Yao H; Yao J; Wang H; Liang X; Hu Z
    Oncotarget; 2017 Jul; 8(29):47052-47063. PubMed ID: 28423362
    [TBL] [Abstract][Full Text] [Related]  

  • 40. GPCR48/LGR4 promotes tumorigenesis of prostate cancer via PI3K/Akt signaling pathway.
    Liang F; Yue J; Wang J; Zhang L; Fan R; Zhang H; Zhang Q
    Med Oncol; 2015 Mar; 32(3):49. PubMed ID: 25636507
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 67.